Premium
Zinopin ® – the rationale for its use as a food supplement in traveller's thrombosis and motion sickness
Author(s) -
Scurr J. H.,
Gulati O. P.
Publication year - 2004
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.1575
Subject(s) - medicine , motion sickness , thrombosis , clinical trial , epidemiology , intensive care medicine , physiology , psychiatry
Venous thrombo‐embolism (VTE) has been associated with periods of prolonged immobility during air, sea and road travel. Motion sickness (MS) has also been reported during both long and short journeys. Current prophylactic therapies for both these indications are generally associated with side effects. Physiological proles of Pycnogenol ® and Standardized Ginger Root Extract (SGRE) representing active constituents of Zinopin ® have been described and reviewed in relation to their activities involved in the patho‐physiology of VTE (Traveller's Sickness) and MS and their safe use as food supplement, in traveller's thrombosis and motion sickness. The patho‐physiology of VTE and MS is discussed in light of epidemiological data and risk factors associated with these conditions. Rationale of development of Zinopin ® and its mechanism of action are discussed based on physiological synergy of Pycnogenol ® and SGRE. Conclusions are made in light of preliminary clinical ndings obtained in an open controlled clinical trial. Further clinical study on Zinopin ® on these lines is suggested. Copyright © 2004 John Wiley & Sons, Ltd.